Last reviewed · How we verify
HES 130/0.4 (Voluven)
HES 130/0.4 is a synthetic colloid that expands intravascular volume by drawing fluid into the bloodstream to maintain hemodynamic stability.
HES 130/0.4 is a synthetic colloid that expands intravascular volume by drawing fluid into the bloodstream to maintain hemodynamic stability. Used for Acute hypovolemia and restoration of circulating blood volume in surgical and trauma patients.
At a glance
| Generic name | HES 130/0.4 (Voluven) |
|---|---|
| Sponsor | The Cleveland Clinic |
| Drug class | Synthetic colloid volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Hydroxyethyl starch (HES) 130/0.4 is a volume expander composed of glucose polymers with a molecular weight of 130 kDa and degree of substitution of 0.4. It functions as a plasma substitute that increases oncotic pressure, drawing interstitial fluid into the intravascular space to restore circulating blood volume in hypovolemic patients. This mechanism helps maintain blood pressure and tissue perfusion during acute blood loss or surgical procedures.
Approved indications
- Acute hypovolemia and restoration of circulating blood volume in surgical and trauma patients
Common side effects
- Acute kidney injury
- Coagulopathy / increased bleeding
- Hyperchloremic acidosis
- Anaphylaxis
Key clinical trials
- Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients (NA)
- Cardiac Output in Preeclamptic (NA)
- Optimizing Fluid Resuscitation in Adults With Major Burns: A Randomized Trial of Burn Navigator™ Versus Parkland Formula (PHASE4)
- Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : Pilot Study in Adult Elective Conventional Cardiac Surgery (PHASE3)
- Colloid Infusion for Optimal Outcomes In Non-cardiac Surgery (COIN Trial) (NA)
- Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HES 130/0.4 (Voluven) CI brief — competitive landscape report
- HES 130/0.4 (Voluven) updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI